ES2363661B2 - Método para el diagnóstico y/o pronóstico de daño renal agudo. - Google Patents
Método para el diagnóstico y/o pronóstico de daño renal agudo. Download PDFInfo
- Publication number
- ES2363661B2 ES2363661B2 ES200901825A ES200901825A ES2363661B2 ES 2363661 B2 ES2363661 B2 ES 2363661B2 ES 200901825 A ES200901825 A ES 200901825A ES 200901825 A ES200901825 A ES 200901825A ES 2363661 B2 ES2363661 B2 ES 2363661B2
- Authority
- ES
- Spain
- Prior art keywords
- expression
- acute renal
- art
- diagnosis
- renal damage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000006378 damage Effects 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000001154 acute effect Effects 0.000 title claims abstract description 23
- 238000003745 diagnosis Methods 0.000 title claims abstract description 15
- 108091028076 Mir-127 Proteins 0.000 claims abstract description 23
- 238000004393 prognosis Methods 0.000 claims abstract description 14
- 108091070501 miRNA Proteins 0.000 claims description 39
- 239000002679 microRNA Substances 0.000 claims description 39
- 210000002966 serum Anatomy 0.000 claims description 19
- 210000002700 urine Anatomy 0.000 claims description 17
- 239000000523 sample Substances 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 230000007170 pathology Effects 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 230000004075 alteration Effects 0.000 claims description 5
- 238000002493 microarray Methods 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 230000008663 renal system process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 34
- 206010021143 Hypoxia Diseases 0.000 description 19
- 230000007954 hypoxia Effects 0.000 description 19
- 235000015097 nutrients Nutrition 0.000 description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- 239000001301 oxygen Substances 0.000 description 17
- 208000009304 Acute Kidney Injury Diseases 0.000 description 11
- 208000033626 Renal failure acute Diseases 0.000 description 11
- 201000011040 acute kidney failure Diseases 0.000 description 11
- 208000012998 acute renal failure Diseases 0.000 description 11
- 208000028867 ischemia Diseases 0.000 description 11
- 230000000302 ischemic effect Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 8
- 208000022638 pyogenic arthritis-pyoderma gangrenosum-acne syndrome Diseases 0.000 description 7
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000007959 normoxia Effects 0.000 description 6
- 235000021232 nutrient availability Nutrition 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 206010063897 Renal ischaemia Diseases 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000003661 Ribonuclease III Human genes 0.000 description 2
- 108010057163 Ribonuclease III Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 208000021709 Delayed Graft Function Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 244000187656 Eucalyptus cornuta Species 0.000 description 1
- 241001643597 Evas Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000013519 Lipocalin-2 Human genes 0.000 description 1
- 108010051335 Lipocalin-2 Proteins 0.000 description 1
- 108091007773 MIR100 Proteins 0.000 description 1
- 108091028066 Mir-126 Proteins 0.000 description 1
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 description 1
- 108091028684 Mir-145 Proteins 0.000 description 1
- 108091062140 Mir-223 Proteins 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000002583 cell-derived microparticle Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108091023685 miR-133 stem-loop Proteins 0.000 description 1
- 108091048308 miR-210 stem-loop Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000015909 regulation of biological process Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200901825A ES2363661B2 (es) | 2009-09-04 | 2009-09-04 | Método para el diagnóstico y/o pronóstico de daño renal agudo. |
| PCT/ES2010/070579 WO2011027019A2 (es) | 2009-09-04 | 2010-09-03 | Metodo para el diagnostico y/o pronostico de daño renal agudo |
| IN1910DEN2012 IN2012DN01910A (enExample) | 2009-09-04 | 2010-09-03 | |
| ES16150622T ES2710332T3 (es) | 2009-09-04 | 2010-09-03 | Método para el diagnostico y/o pronóstico de daño renal agudo |
| MX2012002333A MX2012002333A (es) | 2009-09-04 | 2010-09-03 | Metodo para el diagnostico y/o pronostico de daño renal agudo. |
| AU2010291137A AU2010291137A1 (en) | 2009-09-04 | 2010-09-03 | Method for the diagnosis and/or prognosis of acute renal damage |
| CA2773054A CA2773054A1 (en) | 2009-09-04 | 2010-09-03 | Method for the diagnosis and/or prognosis of acute renal damage |
| RU2012106742A RU2629591C2 (ru) | 2009-09-04 | 2010-09-03 | Способ диагностики и/или прогнозирования острого повреждения почек |
| US13/394,084 US20120172248A1 (en) | 2009-09-04 | 2010-09-03 | Method for the diagnosis and/or prognosis of acute renal damage |
| PT16150622T PT3029156T (pt) | 2009-09-04 | 2010-09-03 | Método para o diagnóstico e/ou prognóstico de lesão renal aguda |
| EP16150622.5A EP3029156B1 (en) | 2009-09-04 | 2010-09-03 | Method for the diagnosis and/or prognosis of acute renal damage |
| JP2012527360A JP5801809B2 (ja) | 2009-09-04 | 2010-09-03 | 急性腎損傷の診断および／または予後方法 |
| EP10813383A EP2474622A4 (en) | 2009-09-04 | 2010-09-03 | METHODS OF DIAGNOSIS AND / OR FORECASTING AKUTER KIDNEY DAMAGE |
| CN201080044847.XA CN102575294B (zh) | 2009-09-04 | 2010-09-03 | 用于急性肾损伤的诊断和/或预后的方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200901825A ES2363661B2 (es) | 2009-09-04 | 2009-09-04 | Método para el diagnóstico y/o pronóstico de daño renal agudo. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2363661A1 ES2363661A1 (es) | 2011-08-11 |
| ES2363661B2 true ES2363661B2 (es) | 2012-05-30 |
Family
ID=43649710
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200901825A Expired - Fee Related ES2363661B2 (es) | 2009-09-04 | 2009-09-04 | Método para el diagnóstico y/o pronóstico de daño renal agudo. |
| ES16150622T Active ES2710332T3 (es) | 2009-09-04 | 2010-09-03 | Método para el diagnostico y/o pronóstico de daño renal agudo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16150622T Active ES2710332T3 (es) | 2009-09-04 | 2010-09-03 | Método para el diagnostico y/o pronóstico de daño renal agudo |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120172248A1 (enExample) |
| EP (2) | EP2474622A4 (enExample) |
| JP (1) | JP5801809B2 (enExample) |
| CN (1) | CN102575294B (enExample) |
| AU (1) | AU2010291137A1 (enExample) |
| CA (1) | CA2773054A1 (enExample) |
| ES (2) | ES2363661B2 (enExample) |
| IN (1) | IN2012DN01910A (enExample) |
| MX (1) | MX2012002333A (enExample) |
| PT (1) | PT3029156T (enExample) |
| RU (1) | RU2629591C2 (enExample) |
| WO (1) | WO2011027019A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2484779A1 (en) * | 2011-02-03 | 2012-08-08 | Medizinische Hochschule Hannover | Device and method for analysis of kidney failure |
| ES2432853B1 (es) * | 2011-12-15 | 2015-03-09 | Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal | Metodo para el diagnostico y/o pronostico de dano renal agudo |
| RU2587012C1 (ru) * | 2014-10-31 | 2016-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ульяновский государственный университет" | Способ прогнозирования острого повреждения почек у больных острым коронарным синдромом |
| RU2583950C1 (ru) * | 2015-05-13 | 2016-05-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования развития острого повреждения почки в условиях тепловой ишемии в эксперименте в зависимости от возраста и пола животных |
| RU2639465C2 (ru) * | 2016-02-24 | 2017-12-21 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" | Способ прогнозирования острого повреждения почек у больных острым коронарным синдромом |
| EP3500270A1 (en) | 2016-08-19 | 2019-06-26 | Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal | Mir-127 agents for use in the treatment of renal fibrosis |
| US11466270B2 (en) | 2016-10-04 | 2022-10-11 | Vib Vzw | Means and methods to treat inflammatory diseases |
| RU2666911C2 (ru) * | 2016-11-24 | 2018-09-13 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт общей патологии и патофизиологии" (ФГБНУ "НИИОПП") | Способ для прогнозирования метастазирования рака яичников на основе группы генов микроРНК |
| TWI646199B (zh) | 2017-10-23 | 2019-01-01 | 長庚醫療財團法人林口長庚紀念醫院 | 用於預測一帶有急性心肌梗塞的人類個體發展出急性腎損傷之風險的方法 |
| RU2702023C1 (ru) * | 2018-08-17 | 2019-10-04 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ диагностики острого повреждения почек после органосохраняющего хирургического лечения локализованного рака почки |
| WO2020071518A1 (ja) * | 2018-10-04 | 2020-04-09 | 学校法人自治医科大学 | 急性腎障害特異的バイオマーカー、急性腎障害の診断方法、急性腎障害の検査用キット、動物治療方法、及び急性腎障害用医薬 |
| RU2703399C1 (ru) * | 2018-11-02 | 2019-10-16 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт общей патологии и патофизиологии" (ФГБНУ "НИИОПП") | Способ для диагностики рака яичников на основе группы генов микроРНК |
| RU2724017C1 (ru) * | 2019-05-17 | 2020-06-18 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" | Способ прогнозирования острого повреждения почек у больных острым коронарным синдромом с использованием шкалы риска |
| EP3929308A1 (en) | 2020-06-23 | 2021-12-29 | Heinrich-Heine-Universität Düsseldorf | Diagnostic methods on renal recovery in individuals suffering from acute kidney injury and suitable biomarkers therefor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7575863B2 (en) * | 2004-05-28 | 2009-08-18 | Applied Biosystems, Llc | Methods, compositions, and kits comprising linker probes for quantifying polynucleotides |
| RU2270605C1 (ru) * | 2004-06-18 | 2006-02-27 | Государственное учреждение научный центр здоровья детей РАМН (ГУ НЦЗД РАМН) | Способ оценки жизнеспособности почечной паренхимы |
| US7833732B2 (en) * | 2005-07-21 | 2010-11-16 | The John Hopkins University | Acute renal injury |
| US20110059537A1 (en) * | 2007-09-20 | 2011-03-10 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for estimating risk of acute kidney injury |
-
2009
- 2009-09-04 ES ES200901825A patent/ES2363661B2/es not_active Expired - Fee Related
-
2010
- 2010-09-03 AU AU2010291137A patent/AU2010291137A1/en not_active Abandoned
- 2010-09-03 EP EP10813383A patent/EP2474622A4/en not_active Withdrawn
- 2010-09-03 WO PCT/ES2010/070579 patent/WO2011027019A2/es not_active Ceased
- 2010-09-03 CN CN201080044847.XA patent/CN102575294B/zh not_active Expired - Fee Related
- 2010-09-03 MX MX2012002333A patent/MX2012002333A/es active IP Right Grant
- 2010-09-03 JP JP2012527360A patent/JP5801809B2/ja not_active Expired - Fee Related
- 2010-09-03 CA CA2773054A patent/CA2773054A1/en not_active Abandoned
- 2010-09-03 RU RU2012106742A patent/RU2629591C2/ru not_active IP Right Cessation
- 2010-09-03 ES ES16150622T patent/ES2710332T3/es active Active
- 2010-09-03 US US13/394,084 patent/US20120172248A1/en not_active Abandoned
- 2010-09-03 PT PT16150622T patent/PT3029156T/pt unknown
- 2010-09-03 EP EP16150622.5A patent/EP3029156B1/en not_active Not-in-force
- 2010-09-03 IN IN1910DEN2012 patent/IN2012DN01910A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2363661A1 (es) | 2011-08-11 |
| CN102575294A (zh) | 2012-07-11 |
| WO2011027019A3 (es) | 2011-04-28 |
| EP3029156A2 (en) | 2016-06-08 |
| EP2474622A4 (en) | 2013-03-06 |
| WO2011027019A2 (es) | 2011-03-10 |
| EP3029156A3 (en) | 2016-09-14 |
| EP3029156B1 (en) | 2018-11-07 |
| CN102575294B (zh) | 2015-07-01 |
| JP2013503617A (ja) | 2013-02-04 |
| ES2710332T3 (es) | 2019-04-24 |
| JP5801809B2 (ja) | 2015-10-28 |
| EP2474622A1 (en) | 2012-07-11 |
| CA2773054A1 (en) | 2011-03-10 |
| US20120172248A1 (en) | 2012-07-05 |
| IN2012DN01910A (enExample) | 2015-07-24 |
| PT3029156T (pt) | 2019-02-11 |
| RU2012106742A (ru) | 2013-10-10 |
| MX2012002333A (es) | 2012-06-12 |
| AU2010291137A1 (en) | 2012-03-15 |
| RU2629591C2 (ru) | 2017-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2363661B2 (es) | Método para el diagnóstico y/o pronóstico de daño renal agudo. | |
| Chen et al. | Effects of long non-coding RNA LINC00667 on renal tubular epithelial cell proliferation, apoptosis and renal fibrosis via the miR-19b-3p/LINC00667/CTGF signaling pathway in chronic renal failure | |
| Morishita et al. | MicroRNA expression profiling in peritoneal fibrosis | |
| ES2676449T3 (es) | Método para el diagnóstico de daño renal agudo | |
| CN104306992A (zh) | 循环miR-210在高血压早期诊断及靶器官损害预警中的应用 | |
| ES2703133T3 (es) | Métodos y composiciones para determinar insuficiencia cardiaca o un riesgo de insuficiencia cardiaca | |
| CN106191251A (zh) | 一种miRNAs心衰标志物及其应用和心衰初筛检测试剂盒 | |
| CN107557472B (zh) | 胶质瘤诊断标志物circ9:135881633|135883078及应用 | |
| ES2374890B1 (es) | Método para el diagnóstico y/o pronóstico de daño renal agudo. | |
| ES2381401B1 (es) | Método para el diagnóstico y/o pronóstico de daño renal agudo. | |
| CN116356009A (zh) | 一种miR-122-5p的应用 | |
| CN107937528B (zh) | 胶质瘤预后标志物hsa_circ_0125365及应用 | |
| CN107604074B (zh) | 胶质瘤预后标志物circ15:101235082|101235577及应用 | |
| Al-Talabani et al. | Mastering noninvasive predictive biomarkers to follow up renal transplant patients | |
| ES2432854B1 (es) | Metodo para el diagnóstico y/o pronóstico de daño renal agudo | |
| CN107937536B (zh) | 胶质瘤预后标志物circ19:47362476|47362693及应用 | |
| CN107619868B (zh) | 胶质瘤预后标志物Circ3:129880309|129880559的应用 | |
| CN108424960A (zh) | 一种LncRNA作为深静脉血栓形成诊断标志物的应用 | |
| RU2678441C1 (ru) | Способ прогнозирования риска развития гипертонической болезни с учетом генетических и средовых факторов | |
| ES2432849B1 (es) | Metodo para el diagnóstico y/o pronóstico de daño renal agudo | |
| McClelland et al. | MicroRNAs as Biomarkers of Diabetic Nephropathy | |
| Clark et al. | Human IL23R R381Q genetic variant implicated in Crohn's disease pathogenesis is hypomorphic resulting in reduced function of the receptor | |
| Iborra et al. | Identification of Serum and Tissue Micro-RNA Expression Profiles in Different Stages of the Inflammatory Bowel Disease | |
| CN108588217A (zh) | 一种LncRNA作为深静脉血栓形成诊断标志物的应用 | |
| Brandl et al. | Forward Genetic Analysis of Gut Homeostasis Using a Sensitized Screen in Mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2363661 Country of ref document: ES Kind code of ref document: B2 Effective date: 20120530 |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20241025 |